Meningococcal antigens
The invention provides proteins from Neisseria meningitidis (strains A & B), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.
1 - 17 . (canceled)
18 . An isolated polypeptide comprising a member selected from the group consisting of
(a) the amino acid sequence of SEQ ID NO: 4; and
(b) an immunogenic fragment of at least 15 contiguous amino acids of SEQ ID NO: 4, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell meditated immune response that recognizes the isolated polypeptide SEQ ID NO: 4.
19 . The isolated polypeptide of claim 18 , wherein the polypeptide is according to (a).
20 . The isolated polypeptide of claim 18 , wherein the polypeptide is according to (b).
21 . The isolated polypeptide of claim 18 , wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:4; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell meditated immune response that recognizes the polypeptide SEQ ID NO: 4.
22 . The isolated polypeptide of claim 18 , wherein the isolated polypeptide consists of SEQ ID NO: 4.
23 . A fusion protein comprising the isolated polypeptide of claim 18 .
24 . An immunogenic composition comprising the polypeptide of claim 18 , and a pharmaceutically acceptable carrier.
25 . The isolated polypeptide of claim 18 , wherein the isolated polypeptide is a recombinant polypeptide.
26 . The isolated polypeptide of claim 19 , wherein the isolated polypeptide is a recombinant polypeptide.
27 . The isolated polypeptide of claim 20 , wherein the isolated polypeptide is a recombinant polypeptide.
28 . An immunogenic composition comprising the isolated polypeptide of claim 19 .
29 . An immunogenic composition comprising the isolated polypeptide of claim 20 .
30 . A fusion protein comprising the isolated polypeptide of claim 19 .
31 . A fusion protein comprising the isolated polypeptide of claim 20.